CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more

In practice

News and in-depth features about business management and career development in optics

Find out more


Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

New DMO treatment arrives in Ireland

Patients now have access to an injection that lasts up to three years


A new treatment has been made available to patients in the Republic of Ireland with chronic diabetic macular oedema (DMO).

Iluvien is an implant that is injected into the affected eye and lasts up to three years, providing a daily micro-dose of the corticosteroid FAc.

It is being made available in Ireland following an agreement between healthcare provider, Vhi, and manufacturer, Alimera Sciences.

Former President of the Irish College of Ophthalmologists, Marie Hickey Dwyer, said that the approval of Iluvien is exciting news for patients who are no longer responding to their first DMO treatment.

“Diabetes remains the most serious cause of severe vision loss in people of working age in Ireland, and DMO is the cause in around 10% of those cases,” she explained.

“The Iluvien implant could mean the difference between a patient having increasingly deteriorating sight, and being able to drive again. I look forward to having it as an option for my patients,” Ms Dwyer added.